- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03552432
The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography (ALTAIR)
The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography: Single Center, Randomized, Open-label, Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Hiromasa Otake, M.D, Ph,D
- Phone Number: +81-78-382-5846
- Email: hotake@med.kobe-u.ac.jp
Study Locations
-
-
Hyogo
-
Kobe, Hyogo, Japan, 650-0017
- Recruiting
- Kobe University Graduate School of Medicine, Department of Cardiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who underwent PCI for ACS or stable coronary heart disease
- Patients with LDL-C ≥70 mg/dL under daily 10mg rosuvastatin
- Patients who have been had TCFA detected by OCT
- Patients aged ≥20 years old at PCI
- Patients who agree to be enrolled in the trial giving signed written informed consent
Exclusion Criteria:
- Patients who have been treated previously with at least one dose of any anti-PCSK9 monoclonal antibody
- Patients had uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) between the time of PCI and randomization visit
- Known hypersensitivity to alirocumab or rosuvastatin
- All contraindications to alirocumab and/or rosuvastatin as displayed in the respective national product labeling for these treatments
- Known history of hemorrhagic stroke
- Currently under treatment for cancer
- Patients on lipoprotein apheresis
- Patients with severe liver or renal dysfunction
- Pregnant or breast-feeding women
- Considered by the investigator as inappropriate for this study for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alirocumab therapy group
start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
|
the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
|
No Intervention: standard statin therapy group
start with only rosuvastatin 10mg per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change in fibrous cap thickness
Time Frame: 9 month
|
the absolute change in minimum fibrous-cap thickness between baseline and 36-week follow-up
|
9 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change in fibrous cap thickness
Time Frame: 9 month
|
the percent change in minimum fibrous-cap thickness between baseline and 36-week follow-up
|
9 month
|
the change in lipid index
Time Frame: 9 month
|
absolute change in lipid index between baseline and 36-week follow-up
|
9 month
|
the change in lipid index
Time Frame: 9 month
|
percentage change in lipid index between baseline and 36-week follow-up
|
9 month
|
the change in lipid length,
Time Frame: 9 month
|
absolute change in lipid core length between baseline and 36-week follow-up
|
9 month
|
the change in lipid length,
Time Frame: 9 month
|
percentage change in lipid core length between baseline and 36-week follow-up
|
9 month
|
the change in mean lipid arc
Time Frame: 9 month
|
absolute change in mean lipid arc between baseline and 36-week follow-up
|
9 month
|
the change in mean lipid arc
Time Frame: 9 month
|
percentage change in mean lipid arc between baseline and 36-week follow-up
|
9 month
|
the change in max lipid arc
Time Frame: 9 month
|
absolute change in max lipid arc between baseline and 36-week follow-up
|
9 month
|
the change in max lipid arc
Time Frame: 9 month
|
percent change in max lipid arc between baseline and 36-week follow-up
|
9 month
|
the change in macrophage grade
Time Frame: 9 month
|
absolute change in summation of macrophage grade between baseline and 36-week follow-up. macrophage grade defined as an OCT macrophage grading system to semiquantify the bright spots based on axial and circumferential distribution, as follows: grade 0, no macrophage; grade 1, localized macrophage accumulation; grade 2, clustered accumulation <1 quadrant; grade 3, clustered accumulation >1 quadrant and ≦3 quadrants; and grade 4, clustered accumulation ≧3 |
9 month
|
the change in macrophage grade
Time Frame: 9 month
|
percentage change in summation of macrophage grade between baseline and 36-week follow-up. macrophage grade defined as an OCT macrophage grading system to semiquantify the bright spots based on axial and circumferential distribution, as follows: grade 0, no macrophage; grade 1, localized macrophage accumulation; grade 2, clustered accumulation <1 quadrant; grade 3, clustered accumulation >1 quadrant and ≦3 quadrants; and grade 4, clustered accumulation ≧3 |
9 month
|
the change in minimum lumen area
Time Frame: 9 month
|
absolute change in minimum lumen area between baseline and 36-week follow-up
|
9 month
|
the change in minimum lumen area
Time Frame: 9 month
|
percentage of change in minimum lumen area between baseline and 36-week follow-up
|
9 month
|
the number of thin-cap fibroatheroma
Time Frame: 9 month
|
change of the number of thin-cap fibroatheroma at 36-week follow-up
|
9 month
|
the change in total cholesterol
Time Frame: 9 month
|
absolute change in serum level of of total cholesterol between baseline and 36-week follow-up
|
9 month
|
the change in total cholesterol
Time Frame: 9 month
|
percent change in serum level of of total cholesterol between baseline and 36-week follow-up
|
9 month
|
the change in LDL-C
Time Frame: 9 month
|
absolute change in serum level of of LDL-C between baseline and 36-week follow-up
|
9 month
|
the change in LDL-C
Time Frame: 9 month
|
percentage change in serum level of of LDL-C between baseline and 36-week follow-up
|
9 month
|
the change in HDL-C
Time Frame: 9 month
|
absolute change in serum level of of HDL-C between baseline and 36-week follow-up
|
9 month
|
the change in HDL-C
Time Frame: 9 month
|
percentage change in serum level of of HDL-C between baseline and 36-week follow-up
|
9 month
|
the change in non-HDL-C
Time Frame: 9 month
|
absolute change in serum level of of non-HDL-C between baseline and 36-week follow-up
|
9 month
|
the change in non-HDL-C
Time Frame: 9 month
|
percentage change in serum level of of non-HDL-C between baseline and 36-week follow-up
|
9 month
|
the change in apolipoprotein B
Time Frame: 9 month
|
absolute change in serum level of of apolipoprotein B between baseline and 36-week follow-up
|
9 month
|
the change in apolipoprotein B
Time Frame: 9 month
|
percentage change in serum level of of apolipoprotein B between baseline and 36-week follow-up
|
9 month
|
the change in Lp(a)
Time Frame: 9 month
|
absolute change in serum level of of Lp (a) between baseline and 36-week follow-up
|
9 month
|
the change in Lp(a)
Time Frame: 9 month
|
percentage change in serum level of of Lp (a) between baseline and 36-week follow-up
|
9 month
|
the change in hs-CRP
Time Frame: 9 month
|
absolute change in serum level of hs-CRP between baseline and 36-week follow-up
|
9 month
|
the change in hs-CRP
Time Frame: 9 month
|
percentage change in serum level of hs-CRP between baseline and 36-week follow-up
|
9 month
|
the change in IL-1β
Time Frame: 9 month
|
absolute change in serum level of IL-1β between baseline and 36-week follow-up
|
9 month
|
the change in IL-1β
Time Frame: 9 month
|
percentage change in serum level of IL-1β between baseline and 36-week follow-up
|
9 month
|
the change in IL-6
Time Frame: 9 month
|
absolute change in serum level of IL-6 between baseline and 36-week follow-up
|
9 month
|
the change in IL-6
Time Frame: 9 month
|
percentage change in serum level of IL-6 between baseline and 36-week follow-up
|
9 month
|
the change in TNF-α
Time Frame: 9 month
|
absolute change in serum level of TNF-α between baseline and 36-week follow-up
|
9 month
|
the change in TNF-α
Time Frame: 9 month
|
percentage change in serum level of TNF-α between baseline and 36-week follow-up
|
9 month
|
the change in MCP-1
Time Frame: 9 month
|
absolute change in serum level of MCP-1 between baseline and 36-week follow-up
|
9 month
|
the change in MCP-1
Time Frame: 9 month
|
percentage change in serum level of MCP-1 between baseline and 36-week follow-up
|
9 month
|
the change in MMP-2
Time Frame: 9 month
|
absolute change in serum level ofMMP-2 between baseline and 36-week follow-up
|
9 month
|
the change in MMP-2
Time Frame: 9 month
|
percentage change in serum level ofMMP-2 between baseline and 36-week follow-up
|
9 month
|
the change in MMP-9
Time Frame: 9 month
|
absolute change in serum level of MMP-9 between baseline and 36-week follow-up
|
9 month
|
the change in MMP-9
Time Frame: 9 month
|
percentage change in serum level of MMP-9 between baseline and 36-week follow-up
|
9 month
|
the change in VCAM-1
Time Frame: 9 month
|
absolute change in serum level of VCAM-1between baseline and 36-week follow-up
|
9 month
|
the change in VCAM-1
Time Frame: 9 month
|
percentage change in serum level of VCAM-1 between baseline and 36-week follow-up
|
9 month
|
the change in ICAM-1
Time Frame: 9 month
|
absolute change in serum level of ICAM-1 between baseline and 36-week follow-up
|
9 month
|
the change in ICAM-1
Time Frame: 9 month
|
percentage change in serum level of ICAM-1 between baseline and 36-week follow-up
|
9 month
|
the change in free PCSK9
Time Frame: 9 month
|
absolute change in serum level of free PCSK9 between baseline and 36-week follow-up
|
9 month
|
the change in free PCSK9
Time Frame: 9 month
|
percentage change in serum level of free PCSK9 between baseline and 36-week follow-up
|
9 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hiromasa Otake, M.D, Ph,D, Kobe University Graduate School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KobeU-290017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Alirocumab
-
Fundación Hipercolesterolemia FamiliarCompletedFamilial HypercholesterolemiaSpain
-
Westside Medical Associates of Los AngelesRegeneron Pharmaceuticals; University of WashingtonUnknownAtherosclerosis | HyperlipidemiaUnited States
-
Population Health Research InstituteCompletedST Elevation Myocardial Infarction | Dyslipidemias | Hypercholesterolemia | Hyperlipidemias | Acute Coronary Syndrome | Physiological Effects of DrugsCanada
-
Shanghai Tong Ren HospitalChina Cardiovascular AssociationRecruitingAcute Myocardial InfarctionChina
-
Regeneron PharmaceuticalsSanofiCompletedHypercholesterolemiaUnited States, Bulgaria, Chile, Estonia, Japan, Mexico, Russian Federation, South Africa, Ukraine
-
University of VirginiaNorthwestern UniversityCompletedPeripheral Arterial DiseaseUnited States
-
Regeneron PharmaceuticalsSanofiTerminatedHeterozygous Familial Hypercholesterolemia | Non-familial HypercholesterolemiaUnited States, Bulgaria, Estonia, Russian Federation, South Africa, Ukraine
-
Washington University School of MedicineCompleted
-
University Hospital Inselspital, BerneRegeneron PharmaceuticalsCompletedCoronary Circulation | Atheroma; Myocardial | Coronary VesselDenmark, Switzerland, Austria, Netherlands
-
Regeneron PharmaceuticalsSanofiCompletedHeterozygous Familial HypercholesterolemiaUnited States, Germany